Advertisement
Canada markets close in 3 hours 9 minutes
  • S&P/TSX

    21,528.29
    -110.81 (-0.51%)
     
  • S&P 500

    5,462.17
    +30.57 (+0.56%)
     
  • DOW

    38,693.52
    +104.36 (+0.27%)
     
  • CAD/USD

    0.7277
    -0.0007 (-0.10%)
     
  • CRUDE OIL

    79.74
    +1.29 (+1.64%)
     
  • Bitcoin CAD

    90,678.96
    -784.88 (-0.86%)
     
  • CMC Crypto 200

    1,375.88
    -12.28 (-0.89%)
     
  • GOLD FUTURES

    2,330.70
    -18.40 (-0.78%)
     
  • RUSSELL 2000

    2,006.92
    +0.76 (+0.04%)
     
  • 10-Yr Bond

    4.2750
    +0.0620 (+1.47%)
     
  • NASDAQ

    17,804.07
    +115.19 (+0.65%)
     
  • VOLATILITY

    12.69
    +0.03 (+0.24%)
     
  • FTSE

    8,142.15
    -4.71 (-0.06%)
     
  • NIKKEI 225

    38,102.44
    -712.12 (-1.83%)
     
  • CAD/EUR

    0.6783
    -0.0015 (-0.22%)
     

Vericel to Present at the Leerink Partners Healthcare Crossroads Conference on Wednesday, May 29, 2024

Vericel Corporation
Vericel Corporation

CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO and Joe Mara, CFO will participate in a fireside chat at the Leerink Partners Healthcare Crossroads Conference at 9:40 a.m. ET on Wednesday, May 29, 2024.

A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com.

About Vericel Corporation

Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives. Vericel markets three products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel also holds an exclusive license for North American rights to NexoBrid® (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adults with deep partial-thickness and/or full-thickness burns. For more information, please visit www.vcel.com.

ADVERTISEMENT

Epicel and MACI are registered trademarks of Vericel Corporation. NexoBrid is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2024 Vericel Corporation. All rights reserved.

Investor Contact:
Eric Burns
ir@vcel.com
+1 (734) 418-4411

Media Contact: 
Julie Downs
media@vcel.com